Significant scientific rigour underpins the development of all QBiotics pharmaceuticals. The dissemination of this research through publication in peer-reviewed journals is a priority for the company. The timing of the release of this information into the public domain is critical to both protect the intellectual property of QBiotics, as well as to optimise opportunities for market launch of registered products. Intellectual property protection via patenting has been successfully implemented with granting in all major regions achieved. Patents for our wound healing pharmaceutical are currently under examination. As such, publication of our data is now underway.
Our publication plan for tigilanol tiglate addresses all the key scientific investigations completed in the drug's development including its:
- Mode of action
- Chemical characterisation
- Clinical efficacy and safety (in human and companion animals)
- Research associated with domestication of the source plant.
Ongoing publication of research and development will build upon the existing published data creating intellectual assets to support the imminent veterinary market launches, as well as to support its clinical development in humans. This approach will be implemented for all other pharmaceuticals in the QBiotics product pipeline.
De Ridder, T. et al. Use of the intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses. Frontiers in Veterinary Science, 09 September, 2020.
De Ridder TR et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC -46). Journal of Veterinary Internal Medicine, June 2020.
Hansen N et al. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of the lesions to topical tigilanol tiglate gel. Veterinary Medicine and Science; 2018
Panizza Benedict J. et al. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine, December 2019
Miller J et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.. Frontiers in Veterinary Science, Volume 6, Article 106, April 2019
Barnett C, et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Investigational New Drugs; April 2018
Boyle G, et al. Intra-lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models, PLOS ONE 2017, Vol 9, Issue 10, page number: e108887
Grant EL et al. Floral and reproductive biology of the medicinally significant rainforest tree, Fontainea picrosperma (Euphorbiaceae) Industrial Crops & Products 108 (2017) 416-422
Lickliter D et al. Phase 1 dose-escalation study of EBC-46 given by intratumoral injection to patients with refractory cutaneous and subcutaneous tumors. Presentation at ASCO Annual Meeting, 2015
Melo, S et al. Intra-tumoral injection of Tigilanol Tiglate in canine mast cell tumors: Time-assessed thermographic images, computed tomography and clinical response. Presentation at Veterinary Cancer Society Annual Conference, 2019
Campbell, J et al. Durability of clinical response to intratumoral tigilanol tiglate in canine MCT. Presentation at Veterinary Cancer Society Annual Conference, 2019
Wiest M. Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors. Presentation at American College of Veterinary Internal Medicine, June 2019
Wiest M. Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors. Presentation at European Society of Veterinary Oncology, May 2019